Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLAXO (GLX) -- Ignore unavailable to you. Want to Upgrade?

To: Zoltan! who wrote (161)	3/1/1998 4:47:00 PM
From: Henry Niman	Respond to of 222

Dow Jones has also picked up the story. Details in the Ex-Merger Table at home.att.net

To: Zoltan! who wrote (161)	3/1/1998 10:05:00 PM
From: Ibnbatutaa	Read Replies (2) \| Respond to of 222

Duncan:Thank you for posting that. GLX is getting desperate.......the loss of Zantac patent protection, and the resulting flood of generic ranitidine is going to make a huge hole in Zantac's sales which still made up a very significant percentage of revenue until last year. The AIDs drugs will not compensate for this loss of revenue in the near future, hence the urgency to merge with / acquire another large company. (Epivir may eventually be approved in the US for Hepatitis B as well: the Far East/ Asia/ MidEast/ Africa will be the major market for this...volume will need to compensate for price). The run up over the past year was illogical given analysts' reports on GLX in 1996 vis a vis Zantac patent loss. Unless Syke's has a "Rabbit in the Hat" this is one to short. I got out of this one last year, still follow it from a distance though. Good luck to those who are still invested.